VESPRO Study 7 – 8 May 2016, Royal Plaza on Scotts Hotel, Singapore
VESPRO study is a prospective meta-analysis of two large-scale randomized control trials-
SIRveNIB [Singapore] and SARAH [France] in advanced hepatocellular carcinoma. The first kick-off meeting was conducted in Paris on 11th Feb 2016 and a follow-up meeting to discuss research collaboration agreement, the protocol, data merging and statistical analysis plan was conducted in Singapore on the 7– 8 May 2016 at the Royal Scotts on Plaza Hotel.
The meeting participants involved Principal Investigator of SIRveNIB, Prof Pierce Chow; Chief
Executive Officer of SCRI, A/Prof Teoh Yee Leong ; Trial Statistician of SIRveNIB and SCRI Head of Biostatistics, Mihir Gandhi; Prinicipal Investigator of SARAH,France, Prof Valerie Vilgrain; Trial Statistician of SARAH & Head of Clinical Research Units, France, Prof Gilles Chatellier; Head of Biostatistics and Research Methodology, NHMRC Clinical Trials Centre, Australia, Prof Val Gebski; Project Manager, Business and Decision, Belgium, Nick De Donder and a few other partners involved in execution of the study.
